Related Experiment Video
Updated: Nov 29, 2025
Iterative Optimization of DNA Duplexes for Crystallization of SeqA-DNA Complexes
Published on: November 1, 2012
Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex
Zhiming Chen1, Qianqian Wang1, Hao Zhang1
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-Jin Hospital, Shanghai JiaoTong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, 197 Rinjin Er Road, Shanghai 200025, China.
MEF2D-fusions drive precursor B-cell acute lymphoblastic leukemia (B-ALL) and indicate poor prognosis. This study reveals the structural information of the MEF2D DNA-binding domain, aiding understanding of B-ALL pathogenesis.
Area of Science:
- Molecular Biology
- Structural Biology
- Hematology
Background:
- MEF2D-fusions are key oncogenic drivers in precursor B-cell acute lymphoblastic leukemia (B-ALL).
- These fusions are linked to poor prognosis in B-ALL patients.
- Understanding the structure of MEF2D is crucial for elucidating its role in leukemogenesis.
Purpose of the Study:
- To express and purify the MEF2D N-terminal DNA binding domain.
- To obtain structural information of the MEF2D-DNA complex.
- To provide insights into the pathogenic mechanisms of MEF2D-fusion-driven B-ALL.
Main Methods:
- Recombinant MEF2D N-terminal DNA binding domain was expressed using the pET-32m vector.
- Protein purification involved affinity, ion-exchange, and gel-filtration chromatography.
- Crystallization of the MEF2D-DNA complex was achieved using specific DNA sequences and PEG1500.
Main Results:
- The MEF2D N-terminal DNA binding domain was purified to >95% purity.
- A MEF2D-DNA crystal of approximately 20 μm³ was obtained at 12 mg/ml.
- X-ray diffraction analysis revealed the crystal diffracted to 4.5 Å resolution in space group P1.
Conclusions:
- The study successfully produced a purified MEF2D DNA-binding domain and crystallized the MEF2D-DNA complex.
- Structural data obtained provides a foundation for understanding MEF2D's role in B-ALL.
- Further structural studies may reveal therapeutic targets for MEF2D-fusion-driven leukemia.
